Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Nervous system disorders – page 60

  • 1 389 clinical trials
  • 585 recruiting
  • 453 conditions
  • 29 countries

Conditions in this area

453 conditions with trials, the busiest first

Dementia Alzheimer's type87Multiple sclerosis59Parkinson's disease56Ischaemic stroke52Migraine48Myasthenia gravis43Glioblastoma40Amyotrophic lateral sclerosis31Duchenne muscular dystrophy28Neuroblastoma26Relapsing multiple sclerosis21Glioma20Relapsing-remitting multiple sclerosis20Narcolepsy19Cognitive disorder18Epilepsy18Giant cell arteritis18Partial seizures18Chronic inflammatory demyelinating polyradiculoneuropathy17Spinal muscular atrophy17Anaesthesia16Subarachnoid haemorrhage16Autism spectrum disorder15Insomnia15+429

Clinical trials in Nervous system disorders

1 389 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

1 389 clinical trials

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Substances:Carboplatin
  • Sponsor:GPOH gGmbH

Giant cell arteritis

Not yet recruiting

Study of bosentan, prednisone and prednisolone in patients with newly diagnosed or relapsing giant cell arteritis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bosentan
  • Sponsor:Assistance Publique Hopitaux De Paris

Parkinson's disease+1

Not yet recruiting

Study of serotonin system changes in early Parkinson's disease using [11C]DASB and [11C]SB207145 PET imaging in people with SNCA gene mutations

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:(1-(11C)METHYLPIPERIDIN-4-YL)METHYL 5-AMINO-6-CHLORO-1,4-BENZODIOXINE-8-CARBOXYLATE
  • Sponsor:Inserm

Dementia

Not yet recruiting

Study on Efgartigimod for Patients with Autoimmune Dementia

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Parkinson's disease

Not yet recruiting

Study on the Safety and Effects of LY3884961 for Patients with Parkinson's Disease and a GBA1 Mutation

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adeno-Associated Viral Vector Serotype 9 Expressing Codon-Optimized Human Gba Gene
  • Sponsor:Prevail Therapeutics Inc.

Amyotrophic lateral sclerosis

Not yet recruiting

Study on the Effectiveness and Safety of Masitinib and Riluzole for Patients with Amyotrophic Lateral Sclerosis (ALS)

Registered drug
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Masitinib
  • Sponsor:Ab Science

Loss of consciousness

Not yet recruiting

Study on Zolpidem's Effects in Patients with Vision Impairments, Disorders of Consciousness, and Neurotypical Volunteers

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Mannitol
  • Sponsor:Universite De Liege

Nervous system disorder+2

Not yet recruiting

Study on the Effects of Dexmedetomidine on Brain Fluid Flow and Activity in Patients with Neurodegenerative Diseases, Delirium, or Acute Neurological Conditions

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · Healthy volunteers
  • Substances:Dexmedetomidine
  • Sponsor:HUS-Yhtymae

Dementia Alzheimer's type

Not yet recruiting

Study on Thiethylperazine and Florbetaben (18F) for Early Alzheimer's Disease Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Florbetaben (18F)
  • Sponsor:Immungenetics AG

Study on the Effects of AD04 and Placebo in Patients with Early Alzheimer's Disease

Not yet recruiting
Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:Aluminium Hydroxide
  • Sponsor:Advantage Therapeutics GmbH

Glycogen storage disease type II

Not yet recruiting

Study on the Effects of Alglucosidase Alfa Enzyme Therapy in Children and Adults with Pompe Disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years · Healthy volunteers
  • Substances:Alglucosidase Alfa
  • Sponsor:Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)

Autism spectrum disorder

Not yet recruiting

Study on Improving Social Interaction in Children with Autism Using Oxytocin Nasal Spray and Therapy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · Healthy volunteers
  • Substances:Oxytocin
  • Sponsor:UZ Leuven

Substances studied in this area

The therapies tested most often in Nervous system disorders trials.

Sodium Chloride72 clinical trialsTemozolomide37 clinical trialsOcrelizumab33 clinical trialsRituximab27 clinical trialsCyclophosphamide25 clinical trialsParacetamol24 clinical trialsCarboplatin15 clinical trialsMethylprednisolone15 clinical trialsPrednisolone15 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.